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Introduction
The diagnosis of  anaphylaxis is based on clinical criteria, hypoten-
sion and shock being not mandatory. Anaphylaxis is unpredict-
able, underrecognized by patients and underdiagnosed by profes-
sionals. [1]
Most chemotherapic agents can lead to hypersensitivity reactions, 
and it is impossible to distinguish between anaphylaxis and acute 
infusion reactions since their symptoms are identical. Paclitaxel 
hypersensitivity reactions incidence is high (8%-45%) but with 
standard premedication (corticosteroids and antihistamines) it 
drops to <10%[2].
We describe a case of  documented anaphylactic reaction to pa-
clitaxel and suggest practical advices for improving its diagnostic 
strategy.
Case report
A 74 years old female was treated with Carboplatin (375 mg) and 
Paclitaxel (299 mg) (once every three weeks) after surgery for a 
right middle lobe NSCLC (pT2N2) and before radiotherapy. De-
spite premedication with dexamethasone, dexchlorpheniramine, 
ranitidine, five minutes after the second Paclitaxel infusion start, 
she presented an anaphylactic reaction with dyspnea, bronchos-
pasma, tachycardia, nausea, vomiting, generalized erythema and 
itching. Hemodynamic and respiratory parameters were pre-
served. After infusion cessation, a rapid remission was obtained 
with oxygen, antihistamines, systemic corticosteroids, intravenous 
antiemetic and inhaled bronchodilators. Paclitaxel was subse-
quently replaced by Vinorelbine with a good tolerance. 
One month before surgery she did experienced a laryngeal angi-
oedema, 5 minutes after intravenous injection of  iodinated con-
trast agents Iobitridol; prick, intradermal and patch tests for these 
agents were negative and Iodixanol was well tolerated.
Nine weeks after anaphylactic reaction, prick tests to Paclitaxel 
(0.01 mg/ml, 0.1 mg/ml, 1 mg/ml) were negative. Intradermal 
reaction was positive at 0.01 mg/ml (9 mm to 18 mm papule in-
crease with erythema). Basophile activation test to Paclitaxel was 
positive.
Comments
Paclitaxel hypersensitivity reactions are frequently described in lit-
Abstract
Most systemic chemotherapic agents used in lung cancer treatment can lead to hypersensitivity reactions, of  varying degrees of  severity. In 
absence of  laboratory tests (such as elevated serum total tryptase or/and plasma histamine levels).Distinguishing
between anaphylaxis and acute infusion reactions is impossible since their symptoms are identical.
Few Paclitaxel hypersensitivity reactions described in literature are documented in the absence of  standardized tests to chemotherapeutics 
drugs and since not all suspected patients undergo allergological tests. A 74 years old female patient, with history of  Inobitriol induced laryn-
geal angioedema and right middle lobe NSCLC, developed a moderate anaphylactic reaction during Paclitaxel second administration. Infusion 
suspension and symptomatic treatments led to rapid symptoms remission. Prick tests to Paclitaxel were negatives but the intradermal reaction 
was positive, as well as basophile activation test.
The mechanism of  paclitaxel-associated hypersensitivity reaction is uncertain and its solvent vehicle may be involved; in case of  paclitaxel 
immediate hypersensitivity reaction, we recommend tryptase and/or histamine serum levels quantification to confirm the acute anaphylaxis 
episode and realization of  allergologicals tests to Paclitaxel and its solvent vehicle (skin tests ± challenge test) 3 to 4 weeks after the incident. 
Rapid desensitization is possible for both Ig-E mediated and non-Ig-E mediated immediate hypersensitivity reactions to Paclitaxel.
Keywords: Paclitaxel Hypersensitivity; Non-Small Cell Lung Cancer; Allergological Tests; Desensitization
International Journal of Clinical & Medical Allergy, 2013 © 2
A. Tiotiu,C. Clément-Duchene, P. Vaillant, Y. Martinet (2013) Anaphylactic Reaction Induced By Paclitaxel in the Treatment of Non-Small Cell Lung Cancer (NSCLC). Int J Clin Med 
Allergy. 1(1), 1-2
erature but few are documented since not all suspected patients 
undergo allergological tests and in the absence of  standardized 
allergological tests to chemotherapeutics drugs. 
The mechanism of  Paclitaxel-associated hypersensitivity reaction 
is uncertain, it may be non-immunological but due to direct his-
tamine release by mast cells. Because of  water insolubility, Pa-
clitaxel is used with a solvent system Cremophor EL, that can 
cause hypersensitivity reactions, neurotoxicity, and alter Paclitaxel 
pharmacokinetics.[2] The respective roles of  Paclitaxel and Cre-
mophor EL are not well defined, since Cremophor EL can cause 
anaphylactic reactions via complement activation.[3]
Our patient symptoms were moderate and it was impossible to 
determine if  the reaction was anaphylactic or acute infusion reac-
tion.[2] Because our patient had two risk factors for anaphylaxis: 
age [1] and a laryngeal angioedema episode induced by Iobitridol 
[4], we suspected Paclitaxel as trigger of  anaphylaxis. Skin tests 
and basophile activation test confirmed Paclitaxel as cause of  the 
anaphylactic reaction.
Recently, a case of  IgE–mediated reaction to Paclitaxel was proved 
by skin and in vitro testing[5]. We didn’t have the opportunity to 
perform an IgE dot-blot assay for our patient. 
For patients with immediate hypersensitivity reactions to Paclitax-
el, we recommend the quantification of  serum tryptase (increased 
15-180 minutes after symptom onset) and/or plasma histamine 
levels (increased 15-60 minutes after symptom onset) to confirm 
anaphylaxis [1] and realization of  allergological tests to Paclitaxel 
and Cremophor EL (skin tests±challenge test) 3-4 weeks after the 
incident. Both Ig-E mediated and non-Ig-E mediated immediate 
hypersensitivity reactions of  any severity are amenable to rapid 
desensitization. [5]
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